PE20091041A1 - Producto de dispersion solida que contiene un compuesto a base de n-aril urea - Google Patents
Producto de dispersion solida que contiene un compuesto a base de n-aril ureaInfo
- Publication number
- PE20091041A1 PE20091041A1 PE2008001785A PE2008001785A PE20091041A1 PE 20091041 A1 PE20091041 A1 PE 20091041A1 PE 2008001785 A PE2008001785 A PE 2008001785A PE 2008001785 A PE2008001785 A PE 2008001785A PE 20091041 A1 PE20091041 A1 PE 20091041A1
- Authority
- PE
- Peru
- Prior art keywords
- acceptable
- solid dispersion
- alcoxy
- union
- absent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UNA DISPERSION SOLIDA QUE COMPRENDE: A) UN GENTE ACTIVO DE FORMULA I, DONDE X1 ES N, CR1; X2 ES N, CR2; X3 ES N, CR3, CR3; X4 ES UNION, N, CR4; X5 ES N, C; Z1 ES O, NH, S; Z2 ES UNION, NH, O; Ar1 ES INDAZOL, ISOQUINOLIN SUSTITUIDO; R1, R3, R5, R6 Y R7 SON CADA UNO H, ALCOXI, ALQUILO, ALQUILTIO, ENTRE OTROS; R2 Y R4 SON CADA UNO H, ALQUENILO, ALCOXI, ALQUILCARBONILO, ENTRE OTROS; R8a ESTA AUSENTE O ES H, ALQUILO; R8b ESTA AUSENTE O ES H, ALCOXI, HALOGENO, ENTRE OTROS ; B) AGENTE FORMADOR DE MATRIZ ACEPTABLE PARA USO FARMACEUTICO SELECCIONADO ENTRE POLI N-VINILPIRROLIDONAS, ACETATO DE VINILO, COPOLIMEROS DE N-VINIL PIRROLIDONA Y COMBINACIONES DE LOS MISMOS; C) UNA COMBINACION DE 2 O MAS TENSIOACTIVOS ACEPTABLES PARA USO FARMACEUTICO DE PREFERENCIA SUCCINATO DE ALFA-TOCOFERIL POLIETILENGLICOL Y GLICERIDO POLALCOXILADO D) AL MENOS UN SOLVENTE. LA RELACION DE MASA ENTRE EL AGENTE ACTIVO Y AGENTE FORMADOR DE MATRIZ ES 0,1:1 Y 1:3. UN AGENTE ACTIVO PREFERIDO ES: N-(5-TERT-BUTIL-2,3-DIHIDRO-1H-INDEN-1-IL)-N'-5-ISOQUINOLINILUREA. DICHO PRODUCTO DE DISPERSION PERMITE UNA FORMULACION SOLIDA DE AGENTE ACTIVOS DE BAJA SOLUBILIDAD CON CONCENTRACION ALTA DE DROGA Y BIODISPONIBILIDAD ACEPTABLE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99961307P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091041A1 true PE20091041A1 (es) | 2009-08-22 |
Family
ID=40089072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001785A PE20091041A1 (es) | 2007-10-19 | 2008-10-17 | Producto de dispersion solida que contiene un compuesto a base de n-aril urea |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090143423A1 (es) |
| EP (1) | EP2197426A2 (es) |
| JP (1) | JP2011500647A (es) |
| KR (1) | KR20100090689A (es) |
| CN (1) | CN101827585A (es) |
| AR (1) | AR068916A1 (es) |
| AU (1) | AU2008313620A1 (es) |
| BR (1) | BRPI0818339A2 (es) |
| CA (1) | CA2699335A1 (es) |
| CL (1) | CL2008003092A1 (es) |
| CO (1) | CO6270303A2 (es) |
| CR (1) | CR11441A (es) |
| DO (1) | DOP2010000114A (es) |
| EC (1) | ECSP10010184A (es) |
| GT (1) | GT201000095A (es) |
| MX (1) | MX2010004292A (es) |
| PE (1) | PE20091041A1 (es) |
| RU (1) | RU2010119924A (es) |
| TW (1) | TW200922549A (es) |
| UA (1) | UA100866C2 (es) |
| UY (1) | UY31406A1 (es) |
| WO (1) | WO2009050289A2 (es) |
| ZA (1) | ZA201002130B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201020236A (en) * | 2008-10-17 | 2010-06-01 | Abbott Lab | TRPV1 antagonists |
| US8609692B2 (en) * | 2008-10-17 | 2013-12-17 | Abbvie Inc. | TRPV1 antagonists |
| US20100210682A1 (en) * | 2009-02-19 | 2010-08-19 | Abbott Laboratories | Repeated Dosing of TRPV1 Antagonists |
| CN102573755A (zh) * | 2009-09-18 | 2012-07-11 | 巴斯夫欧洲公司 | 制备具有低水溶性的物质的制剂的方法 |
| ES2598235T3 (es) * | 2010-12-23 | 2017-01-26 | AbbVie Deutschland GmbH & Co. KG | Formulaciones de retardo sólidas basadas en dispersiones sólidas |
| ES2632979T3 (es) * | 2011-01-10 | 2017-09-18 | Celgene Corporation | Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico |
| EP2797586A1 (en) * | 2011-12-29 | 2014-11-05 | AbbVie Inc. | Solid compositions comprising an hcv inhibitor |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| CN104144682A (zh) | 2013-01-31 | 2014-11-12 | 吉利德法莫赛特有限责任公司 | 两个抗病毒化合物的联用制剂 |
| US9732076B2 (en) | 2013-03-15 | 2017-08-15 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of HCV inhibitor in the amorphous state |
| US10046151B2 (en) | 2013-07-03 | 2018-08-14 | Lts Lohmann Therapie-Systeme, Ag | Transdermal therapeutic system with electronic component |
| KR102239196B1 (ko) | 2013-08-27 | 2021-04-12 | 길리애드 파마셋 엘엘씨 | 2종의 항바이러스 화합물의 조합 제제 |
| ES2924899T3 (es) | 2014-05-20 | 2022-10-11 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que contiene rotigotina |
| CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
| CA2948221C (en) | 2014-05-20 | 2022-11-22 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| WO2016198983A1 (en) | 2015-06-09 | 2016-12-15 | Bend Research Inc. | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| WO2017112693A1 (en) * | 2015-12-22 | 2017-06-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia |
| MY209101A (en) * | 2018-10-30 | 2025-06-21 | Peloton Therapeutics Inc | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof |
| EP4019485B1 (en) | 2019-08-23 | 2024-08-07 | Mochida Pharmaceutical Co., Ltd. | Method for producing heterocyclidene acetamide derivatives |
| CN118812481A (zh) | 2019-08-23 | 2024-10-22 | 持田制药株式会社 | 杂环亚基乙酰胺衍生物的制造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362878A (en) * | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
| SK142694A3 (en) * | 1992-05-28 | 1995-06-07 | Pfizer | N-aryl and n-heteroarylurea derivatives as inhibitors of acylcoenzyme a:cholesterol-acyltransferase, pharmaceutical preparations contains these compounds and use |
| EP1015046A2 (en) * | 1998-07-14 | 2000-07-05 | Em Industries, Inc. | Microdisperse drug delivery systems |
| US7015233B2 (en) * | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
| WO2005123076A2 (en) * | 2004-06-08 | 2005-12-29 | Vertex Pharmaceuticals, Inc. | Pharmaceutical compositions |
| DE602005007048D1 (de) * | 2004-08-27 | 2008-07-03 | Bayer Pharmaceuticals Corp | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs |
| WO2006113631A2 (en) * | 2005-04-18 | 2006-10-26 | Rubicon Research Pvt. Ltd. | Bioenhanced compositions |
| KR100715355B1 (ko) * | 2005-09-30 | 2007-05-07 | 주식회사유한양행 | 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법 |
| US20070104780A1 (en) * | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
| WO2007066189A2 (en) * | 2005-12-09 | 2007-06-14 | Pfizer Products Inc. | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
| US7745448B2 (en) * | 2005-12-28 | 2010-06-29 | Abbott Laboratories Inc. | Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate |
| NZ569700A (en) * | 2006-02-09 | 2011-09-30 | Merck Sharp & Dohme | Polymer formulations of CETP inhibitors |
-
2008
- 2008-10-17 UY UY31406A patent/UY31406A1/es not_active Application Discontinuation
- 2008-10-17 CA CA2699335A patent/CA2699335A1/en not_active Abandoned
- 2008-10-17 BR BRPI0818339 patent/BRPI0818339A2/pt not_active IP Right Cessation
- 2008-10-17 WO PCT/EP2008/064073 patent/WO2009050289A2/en not_active Ceased
- 2008-10-17 EP EP08840773A patent/EP2197426A2/en not_active Withdrawn
- 2008-10-17 JP JP2010529406A patent/JP2011500647A/ja active Pending
- 2008-10-17 MX MX2010004292A patent/MX2010004292A/es not_active Application Discontinuation
- 2008-10-17 RU RU2010119924/15A patent/RU2010119924A/ru not_active Application Discontinuation
- 2008-10-17 CL CL2008003092A patent/CL2008003092A1/es unknown
- 2008-10-17 PE PE2008001785A patent/PE20091041A1/es not_active Application Discontinuation
- 2008-10-17 UA UAA201006030A patent/UA100866C2/ru unknown
- 2008-10-17 CN CN200880112161A patent/CN101827585A/zh active Pending
- 2008-10-17 KR KR1020107010874A patent/KR20100090689A/ko not_active Withdrawn
- 2008-10-17 US US12/253,499 patent/US20090143423A1/en not_active Abandoned
- 2008-10-17 TW TW097140229A patent/TW200922549A/zh unknown
- 2008-10-17 AU AU2008313620A patent/AU2008313620A1/en not_active Abandoned
- 2008-10-17 AR ARP080104542A patent/AR068916A1/es not_active Application Discontinuation
-
2010
- 2010-03-25 ZA ZA2010/02130A patent/ZA201002130B/en unknown
- 2010-04-15 GT GT201000095A patent/GT201000095A/es unknown
- 2010-04-16 DO DO2010000114A patent/DOP2010000114A/es unknown
- 2010-04-27 CO CO10049270A patent/CO6270303A2/es not_active Application Discontinuation
- 2010-05-17 EC EC2010010184A patent/ECSP10010184A/es unknown
- 2010-05-19 CR CR11441A patent/CR11441A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CR11441A (es) | 2010-10-25 |
| EP2197426A2 (en) | 2010-06-23 |
| WO2009050289A2 (en) | 2009-04-23 |
| ECSP10010184A (es) | 2010-06-29 |
| UY31406A1 (es) | 2009-05-29 |
| TW200922549A (en) | 2009-06-01 |
| GT201000095A (es) | 2012-04-03 |
| US20090143423A1 (en) | 2009-06-04 |
| CL2008003092A1 (es) | 2009-11-27 |
| RU2010119924A (ru) | 2011-11-27 |
| AR068916A1 (es) | 2009-12-16 |
| MX2010004292A (es) | 2010-08-02 |
| BRPI0818339A2 (pt) | 2015-04-22 |
| WO2009050289A3 (en) | 2010-03-25 |
| CA2699335A1 (en) | 2009-04-23 |
| AU2008313620A1 (en) | 2009-04-23 |
| DOP2010000114A (es) | 2010-05-15 |
| JP2011500647A (ja) | 2011-01-06 |
| ZA201002130B (en) | 2011-11-30 |
| KR20100090689A (ko) | 2010-08-16 |
| CN101827585A (zh) | 2010-09-08 |
| UA100866C2 (ru) | 2013-02-11 |
| CO6270303A2 (es) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091041A1 (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
| ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| PE20010286A1 (es) | Derivados de indoloxoacetil piperazina como agentes antivirales | |
| PT1093819E (pt) | Compostos e composicoes para fornecimento de agentes activos | |
| ECSP045519A (es) | Nuevos derivados de quinuclidina-amida | |
| UY29058A1 (es) | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato | |
| MXPA06014470A (es) | Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas. | |
| AR045039A1 (es) | Dispositivo de administracion de drogas oftalmicas | |
| ATE327977T1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
| SG164283A1 (en) | New benzimidazole derivatives | |
| UY28763A1 (es) | Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
| ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
| PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
| UY27226A1 (es) | Pirazolopirimidinas como agentes terapéuticos | |
| CL2007001090A1 (es) | Compuestos derivados de diazepano, antagonistas de los receptores ccr-2, ccr-5 y ccr-3; procedimiento de preparacion; composicion farmaceutica; compuesto intermediario; y uso del compuesto en el tratamiento de una enfermedad oclusiva de arterias perifericas, isquemia critica de extremidades, angina inestable, apoplejia, entre otras | |
| CY1105953T1 (el) | Συνθεσεις για απελευθερωση συνδυασμων φαρμακων | |
| ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| PA8586401A1 (es) | 4-piperazinilbencenosulfonilindoles y uso de los mismos | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
| ES2176204T3 (es) | Antidepresivos que contienen un derivado de xantina. | |
| AR024998A1 (es) | Nuevos retinoides para el tratamiento del enfisema | |
| ECSP088603A (es) | Nuevas n-(fluor-pirazinil)-fenilsulfonamidas como moduladores del receptor de quimioquina ccr4 | |
| UY28906A1 (es) | Derivados de pirimidina que son antagonistas del receptor vitronectina | |
| UY28737A1 (es) | Compuestos farmacéuticamente activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |